Characterization and in vitro and in vivo testing of CB2-receptor- and NGAL-targeted paramagnetic micelles for molecular MRI of vulnerable atherosclerotic plaque

Molecular Imaging and Biology

Volumn 12, Issue 6, 2010, Pages 635-651

  Te Boekhorst, Bernard C M ^a,b,f   Bovens, Sandra M ^a,b   Rodrigues Feo, Juan ^a   Sanders, Honorius M H F ^c   Van De Kolk, C W A ^a   De Kroon, Antonius I P M ^d   Cramer, Maarten Jan M ^a   Doevendans, Pieter A F M ^a   Ten Hove, Michiel ^a   Pasterkamp, Gerard ^a   Van Echteld, Cees J A ^a,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

^f CardioMR Laboratory   (Netherlands)

Author keywords

Atherosclerosis; Contrast agent; Macrophages; Micelles; Molecular MRI

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; APOLIPOPROTEIN E; CANNABINOID 2 RECEPTOR; DIOLEOYL POLYETHYLENE GLYCOL PHOSPHATIDYLETHANOLAMINE 1000; DISTEAROYL POLYETHYLENE GLYCOL PHOSPHATIDYLETHANOLAMINE 2000; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHEMICAL LABELING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CONJUGATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HAMSTER; HISTOPATHOLOGY; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MICELLIZATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ACUTE-PHASE PROTEINS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FEASIBILITY STUDIES; LIPOCALINS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MICE; MICE, KNOCKOUT; MICELLES; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS; PHOSPHATIDYLETHANOLAMINES; PLAQUE, ATHEROSCLEROTIC; POLYETHYLENE GLYCOLS; RECEPTOR, CANNABINOID, CB2;

MUS;

EID: 78650516007     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0323-z     Document Type: Article

References (44)

1. E Falk PK Shah V Fuster 1995 Coronary plaque disruption Circulation 92 657 671 1:STN:280:DyaK2MzmtFWlsw%3D%3D 7634481
2. C Yuan M Oikawa Z Miller T Hatsukami 2008 MRI of carotid atherosclerosis J Nucl Cardiol 15 266 275 10.1016/j.nuclcard.2008.02.001 18371599 (Pubitemid 351396322)
3. RM Botnar AS Perez S Witte, et al. 2004 In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent Circulation 109 2023 2029 1:CAS:528:DC%2BD2cXjtFOmtro%3D 10.1161/01.CIR.0000127034.50006.C0 15066940 (Pubitemid 38544494)
4. RM Botnar A Buecker AJ Wiethoff, et al. 2004 In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent Circulation 110 1463 1466 10.1161/01.CIR.0000134960. 31304.87 15238457 (Pubitemid 39238024)
5. PM Winter AM Morawski SD Caruthers, et al. 2003 Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles Circulation 108 2270 2274 1:CAS:528:DC%2BD3sXosVShs7c%3D 10.1161/01.CIR.0000093185.16083.95 14557370 (Pubitemid 37363046)
6. J Barkhausen W Ebert C Heyer JF Debatin HJ Weinmann 2003 Detection of atherosclerotic plaque with gadofluorine-enhanced magnetic resonance imaging Circulation 108 605 609 1:CAS:528:DC%2BD3sXlvVWqsLc%3D 10.1161/01.CIR. 0000079099.36306.10 12835227 (Pubitemid 36961177)
7. MJ Lipinski V Amirbekian JC Frias, et al. 2006 MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor Magn Reson Med 56 601 610 10.1002/mrm.20995 16902977 (Pubitemid 44338879)
8. M Sirol VV Itskovich V Mani, et al. 2004 Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging Circulation 109 2890 2896 1:CAS:528:DC%2BD2cXksF2lu7c%3D 10.1161/01.CIR. 0000129310.17277.E7 15184290 (Pubitemid 38780304)
9. S Steffens NR Veillard C Arnaud, et al. 2005 Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice Nature 434 782 786 1:CAS:528:DC%2BD2MXivFCgtbs%3D 10.1038/nature03389 15815632 (Pubitemid 44739523)
10. F Mach S Steffens 2008 The role of the endocannabinoid system in atherosclerosis J Neuroendocrinol 20 Suppl 1 53 57 1:CAS:528: DC%2BD1cXlsl2iurw%3D 10.1111/j.1365-2826.2008.01685.x 18426500 (Pubitemid 351552677)
11. ZS Galis JJ Khatri 2002 Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 251 262 1:CAS:528:DC%2BD38Xhs1Wrsb4%3D 11861412
12. S Post W Peeters E Busser, et al. 2008 Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density J Vasc Res 45 244 250 1:CAS:528:DC%2BD1cXksFKqtbw%3D 10.1159/000112939 18182823 (Pubitemid 351543148)
13. AL Hemdahl A Gabrielsen C Zhu, et al. 2006 Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction Arterioscler Thromb Vasc Biol 26 136 142 1:CAS:528:DC%2BD2MXhtlagt7vM 10.1161/01.ATV.0000193567.88685.f4 16254208 (Pubitemid 43732240)
14. WJ Mulder GJ Strijkers GA van Tilborg AW Griffioen K Nicolay 2006 Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging NMR Biomed 19 142 164 1:CAS:528:DC%2BD28XisFajsro%3D 10.1002/nbm.1011 16450332 (Pubitemid 43250800)
15. RJ Duncan PD Weston R Wrigglesworth 1983 A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay Anal Biochem 132 68 73 1:CAS:528:DyaL3sXks1Ois74%3D 10.1016/0003-2697(83)90426-8 6353995 (Pubitemid 13030992)
16. R Singh EK Maloney 2002 Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds Anal Biochem 304 47 156 10.1006/abio.2002.5624 (Pubitemid 34522957)
17. PJ Kuhlencordt R Gyurko F Han, et al. 2001 Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice Circulation 104 448 454 1:CAS:528:DC%2BD3MXmtFertbY%3D 10.1161/hc2901.091399 11468208 (Pubitemid 32678276)
18. M Naghavi P Libby E Falk, et al. 2003 From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II Circulation 108 1772 1778 10.1161/01.CIR.0000087481.55887.C9 14557340 (Pubitemid 37296082)
19. S Munro KL Thomas M bu-Shaar 1993 Molecular characterization of a peripheral receptor for cannabinoids Nature 365 61 65 1:CAS:528: DyaK3sXmsVWiurk%3D 10.1038/365061a0 7689702 (Pubitemid 23305569)
20. SM Schwartz TS Hatsukami C Yuan 2001 Molecular markers, fibrous cap rupture, and the vulnerable plaque: new experimental opportunities Circ Res 89 471 473 1:CAS:528:DC%2BD3MXntFGisL8%3D 11557731 (Pubitemid 34132638)
21. L Yan N Borregaard L Kjeldsen MA Moses 2001 The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL J Biol Chem 276 37258 37265 1:CAS:528: DC%2BD3MXns1elu74%3D 10.1074/jbc.M106089200 11486009 (Pubitemid 37384144)
22. D Artemov 2003 Molecular magnetic resonance imaging with targeted contrast agents J Cell Biochem 90 518 524 1:CAS:528:DC%2BD3sXoslemsro%3D 10.1002/jcb.10660 14523986 (Pubitemid 37243699)
23. AN Lukyanov WC Hartner VP Torchilin 2004 Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits J Control Release 94 187 193 1:CAS:528:DC%2BD3sXpslClsb8%3D 10.1016/j.jconrel.2003.10.008 14684282 (Pubitemid 37542388)
24. KC Briley-Saebo PX Shaw WJ Mulder, et al. 2008 Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes Circulation 117 3206 3215 1:CAS:528:DC%2BD1cXnt1ehsrY%3D 10.1161/CIRCULATIONAHA.107.757120 18541740
25. C Oussoren G Storm 1997 Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethylene glycol) Pharm Res 14 1479 1484 1:CAS:528:DyaK2sXntFehtLo%3D 10.1023/A:1012145410859 9358565 (Pubitemid 27481083)
26. J Pintaske P Martirosian H Graf, et al. 2006 Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla Invest Radiol 41 213 221 10.1097/01.rli.0000197668.44926.f7 16481903 (Pubitemid 44406181)
27. TN Parac-Vogt K Kimpe S Laurent, et al. 2006 Paramagnetic liposomes containing amphiphilic bisamide derivatives of Gd-DTPA with aromatic side chain groups as possible contrast agents for magnetic resonance imaging Eur Biophys J 35 136 144 1:CAS:528:DC%2BD28XpsFKi 10.1007/s00249-005-0024-8 16217648 (Pubitemid 43042772)
28. GM Nicolle E Toth KP Eisenwiener HR Macke AE Merbach 2002 From monomers to micelles: investigation of the parameters influencing proton relaxivity J Biol Inorg Chem 7 757 769 1:CAS:528:DC%2BD38Xotlajsbw%3D 10.1007/s00775-002- 0353-3 12203012 (Pubitemid 36056360)
29. AN Lukyanov Z Gao VP Torchilin 2003 Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery J Control Release 91 97 102 1:CAS:528:DC%2BD3sXmsVSktbk%3D 10.1016/S0168-3659(03)00217-7 12932641 (Pubitemid 37288880)
30. VP Torchilin AN Lukyanov Z Gao B Papahadjopoulos-Sternberg 2003 Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs Proc Natl Acad Sci (USA) 100 6039 6044 1:CAS:528:DC%2BD3sXjvFOltLw%3D 10.1073/pnas.0931428100 (Pubitemid 36576927)
31. SA Anderson RK Rader WF Westlin, et al. 2000 Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles Magn Reson Med 44 433 439 1:STN:280:DC%2BD3cvpslWgtQ%3D%3D 10.1002/1522-2594(200009) 44:3<433::AID-MRM14>3.0.CO;2-9 10975896
32. B Gustafsson S Youens AY Louie 2006 Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation Bioconjug Chem 17 538 547 1:CAS:528:DC%2BD28Xhsl2nu7g%3D 10.1021/bc060018k 16536488
33. CJ van Koppen KH Jakobs 2004 Arrestin-independent internalization of G protein-coupled receptors Mol Pharmacol 66 365 367 10.1124/mol.104.003822 15322226 (Pubitemid 39329234)
34. GA van Tilborg WJ Mulder N Deckers, et al. 2006 Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis Bioconjug Chem 17 741 749 10.1021/bc0600259 16704213 (Pubitemid 43794385)
35. TF Massoud SS Gambhir 2003 Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 17 545 580 1:CAS:528:DC%2BD3sXisVejurY%3D 10.1101/gad.1047403 12629038 (Pubitemid 36307540)
36. GJ Strijkers S Hak MB Kok CS Springer Jr K Nicolay 2009 Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents Magn Reson Med 61 1049 1058 10.1002/mrm.21919 19215042
37. E Terreno CS Geninatti S Belfiore, et al. 2006 Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons Magn Reson Med 55 491 497 1:CAS:528: DC%2BD28XivVSgsbo%3D 10.1002/mrm.20793 16450336 (Pubitemid 43352546)
38. MB Kok S Hak WJ Mulder DW van der Schaft GJ Strijkers K Nicolay 2009 Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity Magn Reson Med 61 1022 1032 1:CAS:528:DC%2BD1MXmtVOlurY%3D 10.1002/mrm.21910 19235908
39. X Zeng J Chen YI Miller K Javaherian KS Moulton 2005 Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis J Lipid Res 46 1849 1859 1:CAS:528:DC%2BD2MXhtVSlurzJ 10.1194/jlr.M500241-JLR200 15995169 (Pubitemid 41248481)
40. V Amirbekian MJ Lipinski KC Briley-Saebo, et al. 2007 Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI Proc Natl Acad Sci (USA) 104 961 966 1:CAS:528: DC%2BD2sXhtVSisL4%3D 10.1073/pnas.0606281104 (Pubitemid 46154719)
41. WJ Mulder GJ Strijkers KC Briley-Saboe, et al. 2007 Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles Magn Reson Med 58 1164 1170 10.1002/mrm.21315 18046703 (Pubitemid 350234203)
42. DP Cormode KC Briley-Saebo WJ Mulder, et al. 2008 An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection Small 4 1437 1444 1:CAS:528:DC%2BD1cXhtF2gsLfK 10.1002/smll.200701285 18712752
43. S Laurent LV Elst F Copoix RN Muller 2001 Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment Invest Radiol 36 115 122 1:CAS:528:DC%2BD3MXhtl2itb0%3D 10.1097/00004424- 200102000-00008 11224760 (Pubitemid 32147859)
44. S Hak HM Sanders P Agrawal, et al. 2009 A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging Eur J Pharm Biopharm 72 397 404 1:CAS:528:DC%2BD1MXmtVOjuro%3D 10.1016/j.ejpb.2008.09.017 18940253